Topics:
Genitourinary Cancers • Medical Oncology
How would you approach first-line treatment in a young patient with VHL with intermediate/poor risk metastatic clear cell RCC?
Is there any data as to whether TKI or immunotherapy is more effective in this population?
Answer from: Medical Oncologist at Academic Institution
Currently we still have very little data comparing the use of TKI/IO vs ipi/nivo in the first line setting. Both approaches have demonstrated superiority to single agent TKI (Sunitinib) and would be considered reasonable options.
Currently biomarkers have not had sufficient predictive power to guid...
Sign in or Register to read more